Colin Hutton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Colin Hutton has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Vivian Sze Wing Li
Stem Cell and Cancer Biology Laboratory, The Francis Crick Institute, London, UK
24 shared publications - Angeliki Kanouta
Innate Immune Engineering Laboratory, Department of Developmental Biology and Cancer, Zayed Centre for Research into Rare Diseases in Children, University College London Ormond Street Institute of Child Health, London, United Kingdom
22 shared publications - Ashley Campbell
Barts Cancer Institute
22 shared publications - Callum Baird Nattress
Cell Communication Laboratory, Department of Oncology, University College London Cancer Institute, London, United Kingdom
22 shared publications - Christopher J. Tape
Cell Communication Lab, Department of Oncology, University College London Cancer Institute, London, UK
22 shared publications - Daniel Fowler
Innate Immune Engineering Laboratory, Department of Developmental Biology and Cancer, Zayed Centre for Research into Rare Diseases in Children, University College London Ormond Street Institute of Child Health, London, United Kingdom
22 shared publications
Latest Publications
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Single-cell phenoscaping of γδ T-cell anti-PDO cytotoxicity. A, Experimental design and PDO27 B7-H3 expression measured by flow cytometry. B, γδ T-cell EMD PHATE at phenoscape (middle) and single-cell (insets) resolution. ×180 γδ T-cell–PDO cultures. EMD scores were calculated relative to unmodified-γδ monoculture controls to capture changes during stIL15 transduction and γδ coculture with PDO. C, γδ T PHATE annotated by PDO apoptosis. D, Therapeutic apoptosis via AIC or ADCC per γδ T-cell donor. Mean ± SD of triplicate samples. Two-way ANOVA with Sidak multiple comparisons test. The gray bar compares AIC; the orange bar compares cytotoxicity from AIC + B7-H3 mAb. E, ADCC killing in parental and B7-H3 CRISPR knockout PDO 27 demonstrate antigen specificity of ADCC killing. Unpaired t test (apoptosis values). Mean ± SD of quintuplet samples. F,x̄EMD of γδ T cells in monoculture or coculture with PDO27. Mean of six replicate samples per donor. The reference for x̄EMD scores for all conditions, including monoculture conditions, was calculated relative to monoculture controls. G, γδ T-cell S-phase ± PDOs. Six replicates per donor, with overall mean across all donors plotted. Two-way ANOVA with Tukey multiple comparisons test. H, EMD heatmap of stIL15-γδ T-cell PTM signaling and immunophenotyping markers ± B7-H3 mAb compared with monoculture controls for each stIL15-γδ T-cell donor. EMD scores were calculated relative to monoculture controls for each donor and treatment. ns, not significant; ***, P < 0.001; ****, P < 0.0001.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Single-cell phenoscaping of γδ T-cell anti-PDO cytotoxicity. A, Experimental design and PDO27 B7-H3 expression measured by flow cytometry. B, γδ T-cell EMD PHATE at phenoscape (middle) and single-cell (insets) resolution. ×180 γδ T-cell–PDO cultures. EMD scores were calculated relative to unmodified-γδ monoculture controls to capture changes during stIL15 transduction and γδ coculture with PDO. C, γδ T PHATE annotated by PDO apoptosis. D, Therapeutic apoptosis via AIC or ADCC per γδ T-cell donor. Mean ± SD of triplicate samples. Two-way ANOVA with Sidak multiple comparisons test. The gray bar compares AIC; the orange bar compares cytotoxicity from AIC + B7-H3 mAb. E, ADCC killing in parental and B7-H3 CRISPR knockout PDO 27 demonstrate antigen specificity of ADCC killing. Unpaired t test (apoptosis values). Mean ± SD of quintuplet samples. F,x̄EMD of γδ T cells in monoculture or coculture with PDO27. Mean of six replicate samples per donor. The reference for x̄EMD scores for all conditions, including monoculture conditions, was calculated relative to monoculture controls. G, γδ T-cell S-phase ± PDOs. Six replicates per donor, with overall mean across all donors plotted. Two-way ANOVA with Tukey multiple comparisons test. H, EMD heatmap of stIL15-γδ T-cell PTM signaling and immunophenotyping markers ± B7-H3 mAb compared with monoculture controls for each stIL15-γδ T-cell donor. EMD scores were calculated relative to monoculture controls for each donor and treatment. ns, not significant; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of γδ T cells correlates with anti-PDO cytotoxicity. A, Single-cell PHATE of x10 PDOs + stIL15-γδ T cells ± B7-H3 mAb. B, PDO apoptosis via AIC or ADCC per γδ T donor across x10 PDOs. Two-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. C, Correlation of γδ x̄EMD with anti-PDO cytotoxicity during AIC, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. D, Correlation of γδ x̄EMD with anti-PDO cytotoxicity + B7-H3 mAb, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. E, stIL15-γδ PTM signaling with PDOs ± B7-H3 mAb. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of γδ T cells correlates with anti-PDO cytotoxicity. A, Single-cell PHATE of x10 PDOs + stIL15-γδ T cells ± B7-H3 mAb. B, PDO apoptosis via AIC or ADCC per γδ T donor across x10 PDOs. Two-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. C, Correlation of γδ x̄EMD with anti-PDO cytotoxicity during AIC, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. D, Correlation of γδ x̄EMD with anti-PDO cytotoxicity + B7-H3 mAb, colored by γδ granzyme B. τ denotes the Kendall rank correlation coefficient. E, stIL15-γδ PTM signaling with PDOs ± B7-H3 mAb. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
B7-H3 mAb facilitates Fc receptor–dependant ADCC by stIL15-γδ T cells. A, Therapeutic apoptosis by stIL15-γδ T cells ± mAb ± mAb (Fc null), against colorectal cancer PDO 141. Two-way ANOVA with Dunnett multiple comparisons test. Mean ± SD of triplicate samples. B, Correlation between therapeutic apoptosis and B7-H3 epitope availability. The same clone of B7-H3 mAb was conjugated into the CyTOF staining panel to calculate the relative availability of B7-H3 epitope. C, EMD scores of stIL15-γδ T-cell granzyme B expression calculated relative to untreated coculture controls. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. D, Decrease in stIL15-γδ T-cell % DNAM-1 expression relative to monoculture controls for each treatment. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; ns, not significant.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
B7-H3 mAb facilitates Fc receptor–dependant ADCC by stIL15-γδ T cells. A, Therapeutic apoptosis by stIL15-γδ T cells ± mAb ± mAb (Fc null), against colorectal cancer PDO 141. Two-way ANOVA with Dunnett multiple comparisons test. Mean ± SD of triplicate samples. B, Correlation between therapeutic apoptosis and B7-H3 epitope availability. The same clone of B7-H3 mAb was conjugated into the CyTOF staining panel to calculate the relative availability of B7-H3 epitope. C, EMD scores of stIL15-γδ T-cell granzyme B expression calculated relative to untreated coculture controls. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. D, Decrease in stIL15-γδ T-cell % DNAM-1 expression relative to monoculture controls for each treatment. One-way ANOVA with Sidak multiple comparisons test. Mean ± SD of triplicate samples. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; ns, not significant.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Multimodal γδ T-cell cytotoxicity overcomes cellular therapy immunomodulation. γδ T-cell signaling networks following stIL15 transduction, coculture with PDO, and addition of B7-H3 mAb. Nodes are colored according to γδ EMD scores computed from >4 million cells across 576 conditions. Bottom, γδ cell-state histograms. Each cell-state phase is presented as the mean ± SD (n = 129–138). ITAM, immunoreceptor tyrosine-based activation motif.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Multimodal γδ T-cell cytotoxicity overcomes cellular therapy immunomodulation. γδ T-cell signaling networks following stIL15 transduction, coculture with PDO, and addition of B7-H3 mAb. Nodes are colored according to γδ EMD scores computed from >4 million cells across 576 conditions. Bottom, γδ cell-state histograms. Each cell-state phase is presented as the mean ± SD (n = 129–138). ITAM, immunoreceptor tyrosine-based activation motif.
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of stIL15-γδs signalling and immunophenotype by CRC PDOs with or without anti-B7-H3 mAb
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Regulation of stIL15-γδs signalling and immunophenotype by CRC PDOs with or without anti-B7-H3 mAb
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Phenotype of stIL15-γδ T cells when co-cultured with CRC PDO27
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Phenotype of stIL15-γδ T cells when co-cultured with CRC PDO27
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Relationship between stIL15-γδ cytotoxicity and γδ T cell and PDO phenotypes
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Relationship between stIL15-γδ cytotoxicity and γδ T cell and PDO phenotypes
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Table S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
Table S1 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
StIL15-γδs phenotype regulation by CRC PDOs with or without anti-B7-H3 mAb
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
StIL15-γδs phenotype regulation by CRC PDOs with or without anti-B7-H3 mAb
- Open Access
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
PDOs reciprocally regulate γδ T-cell phenotypes in a patient-specific manner. A, Experimental overview. B, stIL15-γδ EMD-PHATE phenoscape annotated by PDO. EMD scores were calculated relative to stIL15-γδ monoculture controls to capture changes during γδ coculture with PDO. C, γδ T-cell PTM and immunophenotype response to PDOs, including changes in S-phase (IdU). D, Percentage change in immunophenotype marker expression in response to PDOs relative to monoculture controls. E and F,x̄EMD of γδ T cells killing PDOs either by AIC or in the presence of B7-H3 mAb, colored by PDO (E), or γδ T-cell donor (F). One-way ANOVA with Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ns, not significant.
- 14 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation
PDOs reciprocally regulate γδ T-cell phenotypes in a patient-specific manner. A, Experimental overview. B, stIL15-γδ EMD-PHATE phenoscape annotated by PDO. EMD scores were calculated relative to stIL15-γδ monoculture controls to capture changes during γδ coculture with PDO. C, γδ T-cell PTM and immunophenotype response to PDOs, including changes in S-phase (IdU). D, Percentage change in immunophenotype marker expression in response to PDOs relative to monoculture controls. E and F,x̄EMD of γδ T cells killing PDOs either by AIC or in the presence of B7-H3 mAb, colored by PDO (E), or γδ T-cell donor (F). One-way ANOVA with Tukey multiple comparisons test. *, P < 0.05; **, P < 0.01; ns, not significant.